MCL1 and breast cancer: Indeed in an elegant study published while this manuscript was under review, Merino et al.23 demonstrated the potential of MCL-1 inhibition in combination with conventional chemotherapies for increased efficacy in PDX models of TN and HER2-amplified breast cancer.